Barclays
CDIO icon

Barclays’s Cardio Diagnostics CDIO Stock Holding History

Barclays’s Portfolio CDIO Stock Details CDIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-8,671
Closed -$2.61M – 5277
2022
Q3 		$2.61M Hold
8,671
– – ﹤0.01% 1562
2022
Q2 		$2.58M Hold
8,671
– – ﹤0.01% 1672
2022
Q1 		$2.57M Buy
+8,671
New +$2.56M ﹤0.01% 1672

Other funds holding CDIO

LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.02% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.95% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return
ASM
ATW SPAC Management New York $79.2M AUM 10.61% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return
CSC
Caldwell Sutter Capital Sausalito, California $265M AUM 30.15% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays's CDIO Position: Q4 2022 in Review

Barclays sold out of Cardio Diagnostics (CDIO) in Q4 2022, closing a stake of 8,671 shares — an estimated $2.61M sold.

Barclays first reported a position in CDIO in Q1 2022 and held it in 3 quarters. The position peaked at $2.61M in Q3 2022. 11 funds tracked by Wall St. Rank hold CDIO as of Q4 2022.

  • Barclays reported no remaining Cardio Diagnostics position as of Q4 2022 after selling out during the quarter.
  • Barclays sold 8,671 Cardio Diagnostics shares in Q4 2022, an estimated $2.61M.
  • Barclays first reported a position in Cardio Diagnostics in Q1 2022 and held it in 3 quarters.
  • Barclays's Cardio Diagnostics position peaked at $2.61M in Q3 2022.
  • 11 funds tracked by Wall St. Rank held Cardio Diagnostics as of Q4 2022.

Based on Barclays's 13F filing for Q4 2022, filed 13 Feb 2023.